HKU Scholars Hub: Browsing DSpace

Browsing by Author Heathcote, J

Jump to: 0-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 中

or enter first few letters:

Showing results 1 to 10 of 10

	Title	Author(s)	Issue Date	Views
	5-year Follow-up of 998 Chronic Hepatitis B Patients to Determine Long-term Safety of Lamivudine and clinical Consequences of Lamivudine-Resistant Mutations Proceeding/Conference:Hepatology	Lok, AS Lai, CL Leung, N Yao, GB Cui, ZY Schiff, ER Dienstag, JL Heathcote, J Little, NR Griffiths, DA Gardner, SD Castiglia, M	2003
	76 week follow up of HBeAg-positive chronic hepatitis B patients treated with telbivudine, adefovir or switched from adefovir to telbivudine Proceeding/Conference:Journal of Hepatology	Marcellin, P Chan, HLY Lai, CL Cho, M Moon, YM Chao, YC Heathcote, J Myers, R Harb, G Brown, NA	2007	136
	Efficacy of telbivudine vs lamivudine at 2 years in patients with hbeag-positive chronic hepatitis B who are eligible for treatment based on guidelines Proceeding/Conference:Journal of Hepatology	Rasenack, J Poynard, T Lai, CL Gane, E Brown, NA Heathcote, J	2007	124
	Maximal early HBV suppression is predictive of optimal virologic and clinical efficacy in nucleoside-treated hepatitis B patients: scientific observations from a large multinational trial (the GLOBE study) Proceeding/Conference:Hepatology	Lai, CL Gane, E Liaw, YF Thongsawat, S Wang, YM Chen, Y Heathcote, J Rasenack, J Bzowej, N Naoumov, N Chao, G Fielman, B Brown, N the GLOBE Study Group	2005	178
	Optimal virologic and clinical efficacy at one year is associated with maximal early HBV suppression in nucleoside-treated hepatitis B patients Proceeding/Conference:Journal of Hepatology	Zeuzem, S Lai, CL Gane, E Liaw, YF Thongsawat, S Wang, YM Chen, Y Heathcote, J Rasenack, J Bzowej, N Naoumov, N Chao, G Fielman, B Brown, N	2006	147
	Phase III comparison of telbivudine vs lamivudine in HBeAg-positive patients with chronic hepatitis B: Efficacy, safety, and predictors of response at 1 year Proceeding/Conference:Journal of Hepatology	Gane, E Lai, CL Liaw, YF Thongsawat, S Wang, YM Cheng, Y Heathcote, J Rasenack, J Bzowej, N Naoumov, N Chao, G Fielman, B Brown, N	2006
	Phase III Comparison of Telbivudine vs Lamivudine in Patients with Chronic Hepatitis B: Efficacy, Safety, and Predictors of Response at 1 Year Proceeding/Conference:Gastroenterology	Bzowej, N Lai, CL Gane, E Liaw, Y Thongsawat, S Wang, Y Chen, Y Heathcote, J Rasenack, J Naoumov, N Chao, G Fielman, B Brown, N	2006	124
	A randomized trial of telbivudine (LDT) vs. adefovir for HBeAg-positive chronic hepatitis B: Results of the primary week 24 analysis Proceeding/Conference:Journal of Hepatology	Chan, HLY Lai, CL Cho, M Heathcote, J Moon, Y-M Chao, Y-C Myers, R Minuk, G Marcellin, P Jeffers, L Sievert, W Kaiser, R Chao, G Brown, N	2006	139
	Telbivudine (LdT) vs. lmivudine for chronic Hepatitis B: First-year results from the international phase III GLOBE trial Proceeding/Conference:Hepatology	Lai, CL Gane, E Liaw, YF Thongsawat, S Wang, YM Chen, Y Heathcote, J Rasenack, J Bzowej, N Naoumov, N Chao, G Fielman, B Brown, N and the GLOBE Study Group, .	2005
	World gastroenterology organisation practice guideline - hepatitis B September 2008 Journal:South African Gastroenterology Review	Heathcote, J Abbas, Z Alberti, A Benhamou, Y Chen, C Elewaut, A Ferenci, P Hui, C Isakov, V Janssen, H Lau, G Lira, S Okanoue, T OnoNita, S Piratvisuth, T Rizzetto, M Sollano, I Pearman, W Yeh, CT Yuen, M Krabshuis, J	2009

Showing results 1 to 10 of 10